PDF(Pubmed)
Abstract：
UNASSIGNED: Zinc (Zn), an essential trace element, has an adverse influence on the prognosis of several cancers. However, the association between the preoperative serum Zn level and outcomes in patients with advanced esophageal cancer in the current neoadjuvant treatment era remains unclear.
UNASSIGNED: This study involved 185 patients with esophageal cancer who underwent R0 surgery after neoadjuvant chemotherapy from August 2017 to February 2021. We retrospectively investigated the relationship between the preoperative serum Zn level and the patients\' outcomes.
UNASSIGNED: The patients were divided into a low Zn group (<64 μg/dL) and a high Zn group (≤64 μg/dL) according to the mean preoperative serum Zn level. Low Zn had significantly worse overall survival (OS) (2-year OS rate: 76.2% vs. 83.3% in low vs. high Zn; p = 0.044). A low Zn in pathological non-responders (Grade ≤ 1a) was significantly associated with a shorter 2-year recurrence-free survival (RFS) rate (39.6% vs. 64.1% in low vs. high Zn; p = 0.032). The multivariate analysis identified low BMI and Zn level among preoperative nutritional status indices as an independent risk factor for worse RFS in non-responders. Compared with responders, pathological non-responders comprised significantly more males and a performance status of ≥1, and there was no difference in Zn level according to pathological response.
UNASSIGNED: A preoperative low Zn level had a negative impact on early recurrence in esophageal cancer patients who underwent neoadjuvant chemotherapy. This suggests the need to administer Zn supplementation to patients with esophageal cancer who have preoperative Zn deficiency.
UNASSIGNED: This study involved 185 patients with esophageal cancer who underwent R0 surgery after neoadjuvant chemotherapy from August 2017 to February 2021. We retrospectively investigated the relationship between the preoperative serum Zn level and the patients\' outcomes.
UNASSIGNED: The patients were divided into a low Zn group (<64 μg/dL) and a high Zn group (≤64 μg/dL) according to the mean preoperative serum Zn level. Low Zn had significantly worse overall survival (OS) (2-year OS rate: 76.2% vs. 83.3% in low vs. high Zn; p = 0.044). A low Zn in pathological non-responders (Grade ≤ 1a) was significantly associated with a shorter 2-year recurrence-free survival (RFS) rate (39.6% vs. 64.1% in low vs. high Zn; p = 0.032). The multivariate analysis identified low BMI and Zn level among preoperative nutritional status indices as an independent risk factor for worse RFS in non-responders. Compared with responders, pathological non-responders comprised significantly more males and a performance status of ≥1, and there was no difference in Zn level according to pathological response.
UNASSIGNED: A preoperative low Zn level had a negative impact on early recurrence in esophageal cancer patients who underwent neoadjuvant chemotherapy. This suggests the need to administer Zn supplementation to patients with esophageal cancer who have preoperative Zn deficiency.
摘要：
■锌（Zn），一种必需的微量元素，对几种癌症的预后有不利影响。然而,在目前的新辅助治疗时代,术前血清锌水平与晚期食管癌患者预后之间的关系尚不清楚.
■这项研究涉及2017年8月至2021年2月在新辅助化疗后接受R0手术的185例食管癌患者。我们回顾性调查了术前血清锌水平与患者预后之间的关系。
■根据术前平均血清锌水平将患者分为低锌组（<64μg/dL）和高锌组（≤64μg/dL）。低锌的总生存率（OS）明显较差（2年OS率：76.2％vs.83.3%在低位与高锌；p=0.044)。病理性无反应者的低锌（≤1a级）与较短的2年无复发生存率（RFS）显着相关（39.6％vs.64.1%在低位与高锌；p=0.032)。多变量分析确定术前营养状况指标中的低BMI和锌水平是无应答者RFS恶化的独立危险因素。与响应者相比，病理性无反应者包括明显更多的男性，表现状态≥1，根据病理反应，锌水平没有差异。
■术前低锌水平对接受新辅助化疗的食管癌患者的早期复发有负面影响。这表明需要对术前锌缺乏的食管癌患者进行锌补充。
■这项研究涉及2017年8月至2021年2月在新辅助化疗后接受R0手术的185例食管癌患者。我们回顾性调查了术前血清锌水平与患者预后之间的关系。
■根据术前平均血清锌水平将患者分为低锌组（<64μg/dL）和高锌组（≤64μg/dL）。低锌的总生存率（OS）明显较差（2年OS率：76.2％vs.83.3%在低位与高锌；p=0.044)。病理性无反应者的低锌（≤1a级）与较短的2年无复发生存率（RFS）显着相关（39.6％vs.64.1%在低位与高锌；p=0.032)。多变量分析确定术前营养状况指标中的低BMI和锌水平是无应答者RFS恶化的独立危险因素。与响应者相比，病理性无反应者包括明显更多的男性，表现状态≥1，根据病理反应，锌水平没有差异。
■术前低锌水平对接受新辅助化疗的食管癌患者的早期复发有负面影响。这表明需要对术前锌缺乏的食管癌患者进行锌补充。
